会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • A PROCESS FOR THE PURIFICATION OF AQUEOUS EXTRACTS CONTAINING ALLERGENICALLY ACTIVE PROTEINS, EXTRACTS OBTAINABLE ACCORDING TO THIS PROCESS AS WELL AS THEIR USE
    • 含有活性蛋白质的水性提取物的纯化方法,根据本方法可获得的提取物
    • WO1994006821A1
    • 1994-03-31
    • PCT/NL1992000160
    • 1992-09-21
    • LABORATORIOS LETI S.A.BERRENS, Lubertus
    • LABORATORIOS LETI S.A.
    • C07K03/12
    • A61K39/35A61K39/36
    • The invention concerns the removal of various allergologically irrelevant low-molecular weight components from the usual aqueous extracts of allergenically active proteins of plant pollens. Described are the desorption and subsequent elimination, from traditionally prepared allergenic pollen protein extracts, of low-molecular weight pigment and other compounds which are normally retained by strong electrostatic and/or hydrophobic forces. The preparation of such depigmented pollen proteins does not impair their allergenic potency or immunological specificity. The invention enables the production of fully active allergenic pollen proteins devoid of adhering low-molecular weight substances interfering with their safety, diagnostic accuracy and clinical efficacy. The purified pollen proteins represent improved starting materials for chemical derivatization, i.e., the preparation of attenuated vaccines for immunotherapy. The invention also provides suitable products for investigating the molecular structure of allergenic epitopes.
    • 本发明涉及通过植物花粉过敏性活性蛋白质的通常含水提取物去除各种变应原不相关的低分子量组分。 描述了从传统制备的过敏花粉蛋白提取物中解吸和随后的消除低分子量颜料和通常被强烈的静电和/或疏水力保持的其它化合物。 这种脱色花粉蛋白的制备不会损害其过敏效力或免疫特异性。 本发明能够生产没有粘附低分子量物质的完全活性的过敏性花粉蛋白质干扰其安全性,诊断准确性和临床疗效。 纯化的花粉蛋白代表用于化学衍生化的改进起始物质,即用于免疫治疗的减毒疫苗的制备。 本发明还提供了适用于研究过敏原表位的分子结构的产物。
    • 5. 发明申请
    • PURIFICATION OF PROTEINACEOUS MATERIAL
    • 蛋白质材料的纯化
    • WO1994014837A1
    • 1994-07-07
    • PCT/US1993012395
    • 1993-12-17
    • ENZON, INC.
    • ENZON, INC.LEE, Lihsyng, S.MUTHUKUMAR, GanapathyCZUBA, BarbaraSHORR, Robert, G., L.
    • C07K03/12
    • C12Y302/01045A61K38/00C12N9/2402
    • Methods for the purification of proteinaceous materials, such as recombinant glucocerebrosidase (GCS) expressed in an insect cell culture that had been previously infected with a baculovirus carrying GCS-encoding nucleic acid, are disclosed. According to one embodiment, the medium is first clarified by being passed through a hollowfiber cartridge, then bacteria is filtered out. The filtered media is then concentrated with a cation exchange column, followed by hydrophobic interaction chromatography (HIC) purification. In alternative embodiments, the eluate from the cation exchange column and/or the HIC column is passed through an anion exchange column for removal of residual DNA, lipids and endotoxins. The purification methods of the present invention are quicker, cheaper, and capable of handling greater quantities and greater starting purities of conditioned media than processes previously utilized. The various methods of the present invention are also capable of providing commercial quantities of purified GCS suitable for therapeutic uses. Purified forms of GCS are also disclosed.
    • 公开了在先前用携带有GCS编码核酸的杆状病毒感染的昆虫细胞培养物中表达的蛋白质物质如重组葡糖脑苷脂酶(GCS)的纯化方法。 根据一个实施例,首先通过穿过中空纤维筒来澄清培养基,然后将细菌滤出。 然后将过滤的介质用阳离子交换柱浓缩,随后进行疏水相互作用层析(HIC)纯化。 在替代实施方案中,将来自阳离子交换柱和/或HIC柱的洗脱液通过阴离子交换柱以除去残留的DNA,脂质和内毒素。 与先前使用的方法相比,本发明的纯化方法更快,更便宜并且能够处理条件培养基的更大量和更高的起始纯度。 本发明的各种方法还能够提供适合于治疗用途的商业量的纯化GCS。 还公开了纯化形式的GCS。
    • 6. 发明申请
    • AFFINITY PURIFICATION METHODS INVOLVING AMINO ACID MIMETICS AS ELUTION REAGENTS
    • 涉及用作溶液试剂的氨基酸化物质的亲和纯化方法
    • WO1994007912A1
    • 1994-04-14
    • PCT/US1993009174
    • 1993-09-27
    • THE GENERAL HOSPITAL CORPORATION
    • THE GENERAL HOSPITAL CORPORATIONSEED, Brian
    • C07K03/12
    • C07K1/22C07K16/065
    • Disclosed is a method of isolating a protein from a sample, involving (i) providing a first molecule which is capable of forming an affinity complex with the protein; (ii) contacting the sample with the first molecule under conditions which allow affinity complex formation; (iii) isolating the complex; (iv) treating the complex with a second molecule, the second molecule mimicking an amino acid residue of either the protein or the first molecule which is critical to the complex formation, so that the second molecule disrupts the complex; causing the release of the protein from the complex; and (v) isolating the protein. According to one embodiment, the amino acid mimetic imidazole is used as a very gentle elution reagent to disrupt a protein A-antibody fusion protein complex, a technique which has general application for the isolation of antibodies or recombinant antibody fusion proteins.
    • 公开了一种从样品中分离蛋白质的方法,其包括(i)提供能够与蛋白质形成亲和复合物的第一分子; (ii)在允许形成亲和性复合物的条件下使样品与第一分子接触; (iii)分离复合物; (iv)用第二分子处理所述复合物,所述第二分子模拟所述蛋白质或所述第一分子的氨基酸残基对所述复合体形成至关重要,以致所述第二分子破坏所述复合物; 引起蛋白质从复合物的释放; 和(v)分离蛋白质。 根据一个实施方案,氨基酸模拟咪唑用作非常温和的洗脱剂以破坏蛋白A抗体融合蛋白复合物,该技术具有分离抗体或重组抗体融合蛋白的一般应用。